Regulatory approval
Published by the Health Service Executive.
The Republic of Ireland's Health Service Executive (HSE) has approved rituximab in combination with gemcitabine and oxaliplatin for reimbursement as a treatment option for the treatment of relapsed or refractory CD20 positive diffuse large B cell lymphoma in patients ineligible for stem cell transplant.
This is written in the approval document as:
Relapsed or refractory CD20 positive diffuse large B cell lymphoma in patients ineligible for stem cell transplant.
Citation
R-Gemcitabine (1000mg/m2) Oxaliplatin Therapy - 14 day, 2020, version number 4, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/506.pdfTherapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | CD20 + | Diffuse Large B-Cell Lymphoma | Gemcitabine, Oxaliplatin, Rituximab | |
| Sensitivity (+) | CD20 + | Non-Hodgkin Lymphoma | Gemcitabine, Oxaliplatin, Rituximab |